RIVAROXABAN 2.5mg tablets (Xarelto®▼) for the prevention of atherothrombotic events - Pan Mersey APC Skip to main content Help with accessibility Skip to main navigation

RIVAROXABAN 2.5mg tablets (Xarelto®▼) for the prevention of atherothrombotic events

Last Updated: 30 November 2018

Body System: Cardiovascular system

Grey

The Pan Mersey Area Prescribing Committee does not recommend the prescribing of RIVAROXABAN 2.5mg tablets (Xarelto®▼) for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events – in combination with aspirin.